SECURITY AGREEMENT

Contract Categories: Business Finance - Security Agreements
EX-10.16.3 40 d567346dex10163.htm EX-10.16.3 EX-10.16.3

Exhibit 10.16.3

SECURITY AGREEMENT

THIS SECURITY AGREEMENT dated as of December 22, 2008 (“Security Agreement”), is made by BIOCEPT, INC., a California corporation (“Grantor”), in favor of THE REISS FAMILY GST EXEMPT MARITAL DEDUCTION TRUST (“Secured Party”).

RECITALS

A. Secured Party has made and has agreed to make certain advances of money and to extend certain financial accommodations to Grantor as evidenced by that certain Secured Convertible Promissory Note dated December 22, 2008 executed by Grantor in favor of Secured Party and such other Secured Convertible Promissory Notes which may be executed by Grantor in favor of Secured Party after the date hereof (individually, the “Note” and, collectively, the “Notes”) and that certain Note and Warrant Purchase Agreement dated December 22, 2008, by and between Grantor and Secured Party (the “Purchase Agreement”), such advances, future advances, and financial accommodations being referred to herein as the “Loans”.

B. Secured Party is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall have executed and delivered to Secured Party this Security Agreement.

AGREEMENT

NOW, THEREFORE, in order to induce Secured Party to make the Loans and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, and intending to be legally bound, Grantor hereby represents, warrants, covenants and agrees as follows:

1. DEFINED TERMS. When used in this Security Agreement the following terms shall have the following meanings (such meanings being equally applicable to both the singular and plural forms of the terms defined):

“Bankruptcy Code” means Title XI of the United States Code.

“Collateral” shall have the meaning assigned to such term in Section 2 of this Security Agreement.

Contracts” means all contracts (including any customer, vendor, supplier, service or maintenance contract), leases, licenses, undertakings, purchase orders, permits, franchise agreements or other agreements (other than any right evidenced by Chattel Paper, Documents or Instruments), whether in written or electronic form, in or under which Grantor now holds or hereafter acquires any right, title or interest, including, without limitation, with respect to an Account, any agreement relating to the terms of payment or the terms of performance thereof.

“Copyright License” means any agreement, whether in written or electronic form, in which Grantor now holds or hereafter acquires any interest, granting any right in or to any Copyright or Copyright registration (whether Grantor is the licensee or the licensor thereunder)

 

1.


including, without limitation, licenses pursuant to which Grantor has obtained the exclusive right to use a copyright owned by a third party.

Copyrights” means all of the following now owned or hereafter acquired or created (as a work for hire for the benefit of Grantor) by Grantor or in which Grantor now holds or hereafter acquires or receives any right or interest, in whole or in part: (a) all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof or any other country; (b) registrations, applications, recordings and proceedings in the United States Copyright Office or in any similar office or agency of the United States, any State thereof or any other country; (c) any continuations, renewals or extensions thereof; (d) any registrations to be issued in any pending applications, and shall include any right or interest in and to work protectable by any of the foregoing which are presently or in the future owned, created or authorized (as a work for hire for the benefit of Grantor) or acquired by Grantor, in whole or in part; (e) prior versions of works covered by copyright and all works based upon, derived from or incorporating such works; (f) income, royalties, damages, claims and payments now and hereafter due and/or payable with respect to copyrights, including, without limitation, damages, claims and recoveries for past, present or future infringement; (g) rights to sue for past, present and future infringements of any copyright; and (h) any other rights corresponding to any of the foregoing rights throughout the world.

“Event of Default” any “Event of Default” as defined in the Notes.

Intellectual Property” means any intellectual property, in any medium, of any kind or nature whatsoever, now or hereafter owned or acquired or received by Grantor or in which Grantor now holds or hereafter acquires or receives any right or interest, and shall include, in any event, any Copyright, Copyright License, Trademark, Trademark License, Patent, Patent License, trade secret, customer list, marketing plan, internet domain name (including any right related to the registration thereof), proprietary or confidential information, mask work, source, object or other programming code, invention (whether or not patented or patentable), technical information, procedure, design, knowledge, know-how, software, data base, data, skill, expertise, recipe, experience, process, model, drawing, material or record.

License” means any Copyright License, Patent License, Trademark License or other license of rights or interests, whether in-bound or out-bound, whether in written or electronic form, now or hereafter owned or acquired or received by Grantor or in which Grantor now holds or hereafter acquires or receives any right or interest, and shall include any renewals or extensions of any of the foregoing thereof.

“Lien” means any mortgage, lien, deed of trust, charge, pledge, security interest or other encumbrance.

Money” means a medium of exchange authorized or adopted by a domestic or foreign government and includes a monetary unit of account established by an intergovernmental organization or by agreement between two or more nations.

“Patent License” means any agreement, whether in written or electronic form, in which Grantor now holds or hereafter acquires any interest, granting any right with respect to any

 

2.


invention on which a Patent is in existence (whether Grantor is the licensee or the licensor thereunder).

Patents” means all of the following in which Grantor now holds or hereafter acquires any interest: (a) all letters patent of the United States or any other country, all registrations and recordings thereof and all applications for letters patent of the United States or any other country, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country; (b)all reissues, divisions, continuations, renewals, continuations-in-part or extensions thereof; (c) all petty patents, divisionals and patents of addition; (d) all patents to issue in any such applications; (e) income, royalties, damages, claims and payments now and hereafter due and/or payable with respect to patents, including, without limitation, damages, claims and recoveries for past, present or future infringement; and (f) rights to sue for past, present and future infringements of any patent.

Permitted Lien” means: (a) any Liens existing on the date of this Security Agreement and set forth on Schedule A attached hereto; (b) Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested in good faith by appropriate proceedings; (c) Liens (i) upon or in any Equipment acquired or held by Grantor to secure the purchase price of such Equipment or indebtedness (including capital leases) incurred solely for the purpose of financing the acquisition of such Equipment or (ii) existing on such Equipment at the time of its acquisition, provided that the Lien is confined solely to the Equipment so acquired, improvements thereon and the Proceeds of such Equipment; (d) leases or subleases and licenses or sublicenses granted to others in the ordinary course of Grantor’s business if such are not otherwise prohibited under this Security Agreement and do not interfere in any material respect with the business of Grantor; (e) any right, title or interest of a licensor under a license; (f) Liens arising from judgments, decrees or attachments to the extent and only so long as such judgment, decree or attachment has not caused or resulted in an Event of Default; (g) easements, reservations, rights-of-way, restrictions, minor defects or irregularities in title and other similar Liens affecting real property not interfering in any material respect with the ordinary conduct of the business of Grantor; (h) Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods; (i) Liens arising solely by virtue of any statutory or common law provision relating to banker’s liens, rights of setoff or similar rights and remedies as to deposit accounts or other funds maintained with a creditor depository institution; (j) Liens in favor of a depository bank or a securities intermediary pursuant to such depository bank’s or securities intermediary’s customary customer account agreement; provided that any such Liens shall at no time secure any indebtedness or obligations other than customary fees and charges payable to such depository bank or securities intermediary; (k) statutory or common law Liens of landlords and carriers, warehousemen, mechanics, suppliers, materialmen, repairmen and other similar Liens, arising in the ordinary course of business and securing obligations that are not yet delinquent or are being contested in good faith by appropriate proceedings; (l) Liens incurred or deposits made to secure the performance of tenders, bids, leases, statutory or regulatory obligations, surety and appeal bonds, government contracts, performance and return-of-money bonds, and other obligations of like nature, in each case, in the ordinary course of business; (m) Liens incurred or deposits made in the ordinary course of business in connection with workers’ compensation, unemployment insurance and other types of social security; (n) pledges and deposits securing liability for

 

3.


reimbursement or indemnification obligations in respect of letters of credit or bank guarantees for the benefit of landlords; and (o) Liens incurred in connection with the extension, renewal or refinancing of indebtedness secured by Liens permitted under the preceding clauses, provided that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness being extended, renewed or refinanced does not increase.

Secured Obligations” means (a) the obligation of Grantor to repay Secured Party all of the unpaid principal amount of, and accrued interest on (including any interest that accrues after the commencement of bankruptcy), the Loans, and (b) the obligation of Grantor to pay any fees, costs and expenses of Secured Party under the Notes, the Purchase Agreement, or this Security Agreement.

Security Agreement” means this Security Agreement and all Schedules hereto, as the same may from time to time be amended, modified, supplemented or restated.

Trademark License” means any agreement, whether in written or electronic form, in which Grantor now holds or hereafter acquires any interest, granting any right in and to any Trademark or Trademark registration (whether Grantor is the licensee or the licensor thereunder).

Trademarks” means any of the following in which Grantor now holds or hereafter acquires any interest: (a) any trademarks, tradenames, corporate names, company names, business names, trade styles, service marks, logos, other source or business identifiers, prints and labels on which any of the foregoing have appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof and any applications in connection therewith, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country (collectively, the “Marks”); (b) any reissues, extensions or renewals thereof; (c) the goodwill of the business symbolized by or associated with the Marks; (d) income, royalties, damages, claims and payments now and hereafter due and/or payable with respect to the Marks, including, without limitation, damages, claims and recoveries for past, present or future infringement; and (e) rights to sue for past, present and future infringements of the Marks.

UCC” means the Uniform Commercial Code as the same may from time to time be in effect in the State of California (and each reference in this Security Agreement to an Article thereof (denoted as a Division of the UCC as adopted and in effect in the State of California) shall refer to that Article (or Division, as applicable) as from time to time in effect, which in the case of Article 9 shall include and refer to Revised Article 9 from and after the date Revised Article 9 shall become effective in the State of California); provided, however, in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of Secured Party’s security interest in any Collateral is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of California, the term “UCC” shall mean the Uniform Commercial Code (including the Articles thereof) as in effect at such time in such other jurisdiction for purposes of the provisions hereof relating to such attachment, perfection or priority and for purposes of definitions related to such provisions.

 

4.


In addition, the following terms shall be defined terms having the meaning set forth for such terms in the UCC: “Account”, “Account Debtor”, “Chattel Paper”, “Commodity Account”, “Deposit Account”, “Documents”, “Equipment”, “Fixtures”, “General Intangible”, “Goods”, “Instrument”, “Inventory”, “Investment Property”, “Letter-of-Credit Right”, “Money”, “Payment Intangibles”, “Proceeds”, “Promissory Notes”, “Securities Account”, and “Supporting Obligations”. Each of the foregoing defined terms shall include all of such items now owned, or hereafter acquired, by Grantor.

2. GRANT OF SECURITY INTEREST. As collateral security for the full, prompt, complete and final payment and performance when due (whether at stated maturity, by acceleration or otherwise) of all the Secured Obligations and in order to induce Secured Party to cause the Loans to be made, Grantor hereby assigns, conveys, mortgages, pledges, hypothecates and transfers to Secured Party, and hereby grants to Secured Party, a security interest in all of Grantor’s right, title and interest in, to and under the following, whether now owned or hereafter acquired (all of which being collectively referred to herein as the “Collateral”):

(a) All Accounts of Grantor;

(b) All Chattel Paper of Grantor;

(c) All Commodity Accounts of Grantor;

(d) All Contracts of Grantor;

(e) All Deposit Accounts of Grantor;

(f) All Documents of Grantor;

(g) All General Intangibles of Grantor, including, without limitation, Intellectual Property;

(h) All Goods of Grantor, including, without limitation, Equipment, Inventory and Fixtures;

(i) All Instruments of Grantor, including, without limitation, Promissory Notes;

(j) All Investment Property of Grantor;

(k) All Letter-of Credit Rights of Grantor;

(l) All Money of Grantor;

(m) All Securities Accounts of Grantor;

(n) All Supporting Obligations of Grantor;

(o) All property of Grantor held by Secured Party, or any other party for whom Secured Party is acting as agent, including, without limitation, all property of every-description

 

5.


now or hereafter in the possession or custody of or in transit to Secured Party or such other party for any purpose, including, without limitation, safekeeping, collection or pledge, for the account of Grantor, or as to which Grantor may have any right or power;

(p) All other goods and personal property of Grantor, wherever located, whether tangible or intangible, and whether now owned or hereafter acquired, existing, leased or consigned by or to Grantor; and

(q) To the extent not otherwise included, all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for and rents, profits and products of each of the foregoing.

Notwithstanding the foregoing provisions of this Section 2, the grant, assignment and transfer of a security interest as provided herein shall not extend to, and the term “Collateral” shall not include: (a) “intent-to-use” trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise or (b) any Account, Chattel Paper, General Intangible or Promissory Note in which Grantor has any right, title or interest if and to the extent such Account, Chattel Paper, General Intangible or Promissory Note includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Grantor therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person party to such Account, Chattel Paper, General Intangible or Promissory Note to enforce any remedy with respect thereto; provided that the foregoing exclusion shall not apply if (i) such prohibition has been waived or such other person has otherwise consented to the creation hereunder of a security interest in such Account, Chattel Paper, General Intangible or Promissory Note or (ii) such prohibition would be rendered ineffective pursuant to Sections 9-406(d), 9-407(a) or 9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code) or principles of equity); provided further that immediately upon the ineffectiveness, lapse or termination of any such provision, the Collateral shall include, and Grantor shall be deemed to have granted on the date hereof a security interest in, all its rights, title and interests in and to such Account, Chattel Paper, General Intangible or Promissory Note as if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect Secured Party’s unconditional continuing security interest in and to all rights, title and interests of Grantor in or to any payment obligations or other rights to receive monies due or to become due under any such Account, Chattel Paper, General Intangible or Promissory Note and in any such monies and other proceeds of such Account, Chattel Paper, General Intangible or Promissory Note.

3. RIGHTS OF SECURED PARTY; COLLECTION OF ACCOUNTS.

(a) Notwithstanding anything contained in this Security Agreement to the contrary, Grantor expressly agrees that it shall remain liable under each of its Contracts, Chattel Paper, Documents, Instruments and Licenses to observe and perform all the conditions and obligations to be observed and performed by it thereunder and that it shall perform all of its duties and obligations thereunder, all in accordance with and pursuant to the terms and provisions of each such Contract, Chattel Paper, Document, Instrument or License. Secured

 

6.


Party shall not have any obligation or liability under any such Contract, Chattel Paper, Document, Instrument, or License by reason of or arising out of this Security Agreement or the granting to Secured Party of a lien therein or the receipt by Secured Party of any payment relating to any such Contract, Chattel Paper, Document, Instrument, or License pursuant hereto, nor shall Secured Party be required or obligated in any manner to perform or fulfill any of the obligations of Grantor under or pursuant to any such Contract, Chattel Paper, Document, Instrument, or License, or to make any payment, or to make any inquiry as to the nature or the sufficiency of any payment received by it or the sufficiency of any performance by any party under any such Contract, Chattel Paper, Document, Instrument, or License, or to present or file any claim, or to take any action to collect or enforce any performance or the payment of any amounts which may have been assigned to it or to which it may be entitled at any time or times.

(b) Secured Party authorizes Grantor to collect its Accounts. At the request of Secured Party, Grantor shall deliver all original and other documents evidencing and relating to the performance of labor or service which created such Accounts, including, without limitation, all original orders, invoices and shipping receipts.

(c) Secured Party may at any time, upon the occurrence and during the continuance of any Event of Default, notify Account Debtors of Grantor, parties to the Contracts of Grantor, and obligors in respect of Instruments of Grantor and obligors in respect of Chattel Paper of Grantor that the Accounts and the right, title and interest of Grantor in and under such Contracts, Instruments and Chattel Paper have been assigned to Secured Party and that payments shall be made directly to Secured Party. Upon the occurrence and during the continuance of any Event of Default, upon the request of Secured Party, Grantor shall so notify such Account Debtors, parties to such Contracts, obligors in respect of such Instruments and obligors in respect of such Chattel Paper. Secured Party may, in its name or in the name of others, communicate with such Account Debtors, parties to such Contracts, obligors in respect of such Instruments and obligors in respect of such Chattel Paper to verify with such parties, to Secured Party’s satisfaction, the existence, amount and terms of any such Accounts, Contracts, Instruments or Chattel Paper.

4. REPRESENTATIONS AND WARRANTIES. Grantor hereby represents and warrants to Secured Party that:

(a) Except for the security interest granted to Secured Party under this Security Agreement and Permitted Liens, Grantor is the sole legal and equitable owner of each item of the Collateral in which it purports to grant a security interest hereunder.

(b) No effective security agreement, financing statement, equivalent security or lien instrument or continuation statement covering all or any part of the Collateral exists, except such as may have been filed by Grantor in favor of Secured Party pursuant to this Security Agreement and except for Permitted Liens.

(c) This Security Agreement creates a legal and valid security interest on and in all of the Collateral in which Grantor now has rights.

 

7.


(d) Grantor’s taxpayer identification number is set forth in the signature page hereof. Grantor’s chief executive office, principal place of business, and the place where Grantor maintains its records concerning the Collateral are presently located at the address set forth on the signature page hereof. The Collateral consisting of goods, other than motor vehicles and such other mobile goods, is presently located at such address and at such additional addresses set forth on Schedule B attached hereto.

(e) All Collateral of Grantor consisting of Chattel Paper, Instruments or Investment Property is set forth on Schedule C attached hereto.

(f) The name and address of each depository institution at which Grantor maintains any Deposit Account and the account number and account name of each such Deposit Account is listed on Schedule D attached hereto. The name and address of each securities intermediary or commodity intermediary at which Grantor maintains any Securities Account or Commodity Account and the account number and account name is listed on Schedule D attached hereto. Grantor agrees to amend Schedule D upon Secured Party’s request to reflect the opening of any additional Deposit Account, Securities Account or Commodity Account, or closing or changing the account name or number on any existing Deposit Account, Securities Account, or Commodity Account.

(g) All Intellectual Property now owned or held by the Grantor are listed on Schedule E attached hereto.

5. COVENANTS. Unless Secured Party otherwise consents (which consent shall not be unreasonably withheld), Grantor covenants and agrees with Secured Party that from and after the date of this Security Agreement and until the Secured Obligations have been performed and paid in full (other than inchoate indemnity obligations) and any commitment of Secured Party to make Loans to Grantor has expired or terminated:

5.1 Disposition of Collateral. Grantor shall not sell, lease, transfer or otherwise dispose of any of the Collateral (each, a “Transfer”), or attempt or contract to do so, other than (a) the sale of Inventory in the ordinary course of business, (b) the granting of Licenses in the ordinary course of business and (c) the disposal of worn-out or obsolete Equipment.

5.2 Change of Jurisdiction of Organization, Relocation of Business. Grantor shall not change its jurisdiction of organization or relocate its chief executive office, principal place of business or its records from such address(es) provided to Secured Party pursuant to Section 4(d) above without at least seven (7) days prior notice to Secured Party.

5.3 Limitation on Liens on Collateral. Grantor shall not, directly or indirectly, create, permit or suffer to exist, and shall defend the Collateral against and take such other action as is necessary to remove, any Lien on the Collateral, except (a) Permitted Liens and (b) the Lien granted to Secured Party under this Security Agreement.

 

8.


5.4 Insurance. Grantor shall maintain insurance policies insuring the Collateral against loss or damage from such risks and in such amounts and forms and with such companies as are customarily maintained by businesses similar to Grantor.

5.5 Taxes, Assessments, Etc. Grantor shall pay promptly when due all property and other taxes, assessments and government charges or levies imposed upon, and all claims (including claims for labor, materials and supplies) against, the Goods, except to the extent the validity or amount thereof is being contested in good faith and adequate reserves are being maintained in connection therewith.

5.6 Defense of Intellectual Property. Grantor shall use commercially reasonable efforts to (i) protect, defend and maintain the validity and enforceability of all Copyrights, Patents and Trademarks material to Grantor’s business and (ii) detect infringements of all Copyrights, Patents and Trademarks material to Grantor’s business.

5.7 Further Assurances. At any time and from time to time, upon the written request of Secured Party, and at the sole expense of Grantor, Grantor shall promptly and duly execute and deliver any and all such further instruments and documents and take such further action as Secured Party may reasonably deem necessary or desirable to obtain the full benefits of this Security Agreement, including, without limitation, (a) executing, delivering and causing to be filed any financing or continuation statements (including “in lieu” continuation statements) under the UCC with respect to the security interests granted hereby, (b) at Secured Party’s reasonable request, filing or cooperating with Secured Party in filing any forms or other documents required to be recorded with the United States Patent and Trademark Office, United States Copyright Office, (c) at Secured Party’s reasonable request, placing the interest of Secured Party as lienholder on the certificate of title (or similar evidence of ownership) of any vehicle, watercraft or other Equipment constituting Collateral owned by Grantor which is covered by a certificate of title (or similar evidence of ownership), (d) executing and delivering and using commercially reasonable efforts to cause the applicable depository institution, securities intermediary, commodity intermediary or issuer or nominated party under a letter of credit to execute and deliver a collateral control agreement with respect to any Deposit Account, Securities Account or Commodity Account or Letter-of-Credit Right in or to which Grantor has any right or interest and (e) at Secured Party’s reasonable request, using commercially reasonable efforts to obtain acknowledgments from bailees having possession of any Collateral and waivers of liens from landlords and mortgagees of any location where any of the Collateral may from time to time be stored or located. Grantor also hereby authorizes Secured Party to file any such financing or continuation statement (including “in lieu” continuation statements) without the signature of Grantor.

6. SECURED PARTYS APPOINTMENT AS ATTORNEY-IN-FACT; PERFORMANCE BY SECURED PARTY.

(a) Subject to Section 6(b) below, Grantor hereby irrevocably constitutes and appoints Secured Party, and any officer or agent of Secured Party, with full power of substitution, as its true and lawful attorney-in-fact with full, irrevocable power and authority in the place and stead of Grantor and in the name of Grantor or in its own name, from time to time at Secured Party’s discretion, for the purpose of carrying out the terms of this Security

 

9.


Agreement, to take any and all appropriate action and to execute and deliver any and all documents and instruments which may be necessary or desirable to accomplish the purposes of this Security Agreement and, without limiting the generality of the foregoing, hereby gives Secured Party the power and right, on behalf of Grantor, without notice to or assent by Grantor to do the following:

(i) to ask, demand, collect, receive and give acquittances and receipts for any and all monies due or to become due under any Collateral and, in the name of Grantor, in its own name or otherwise to take possession of, endorse and collect any checks, drafts, notes, acceptances or other Instruments for the payment of monies due under any Collateral and to file any claim or take or commence any other action or proceeding in any court of law or equity or otherwise deemed appropriate by Secured Party for the purpose of collecting any and all such monies due under any Collateral whenever payable;

(ii) to pay or discharge any Liens, including, without limitation, any tax lien, levied or placed on or threatened against the Collateral, to effect any repairs or any insurance called for by the terms of this Security Agreement and to pay all or any part of the premiums therefor and the costs thereof, which actions shall be for the benefit of Secured Party and not Grantor;

(iii) to (1) direct any person liable for any payment under or in respect of any of the Collateral to make payment of any and all monies due or to become due thereunder directly to Secured Party or as Secured Party shall direct, (2) receive payment of any and all monies, claims and other amounts due or to become due at any time arising out of or in respect of any Collateral, (3) sign and endorse any invoices, freight or express bills, bills of lading, storage or warehouse receipts, drafts against debtors, assignments, verifications and notices in connection with Accounts and other Instruments and Documents constituting or relating to the Collateral, (4) commence and prosecute any suits, actions or proceedings at law or in equity in any court of competent jurisdiction to collect the Collateral or any part thereof and to enforce any other right in respect of any Collateral, (5) defend any suit, action or proceeding brought against Grantor with respect to any Collateral, (6) settle, compromise or adjust any suit, action or proceeding described above, and in connection therewith, give such discharges or releases as Secured Party may deem appropriate, (7) license, or, to the extent permitted by an applicable License, sublicense, whether general, special or otherwise, and whether on an exclusive or non-exclusive basis, any Copyright, Patent or Trademark throughout the world for such term or terms, on such conditions and in such manner as Secured Party shall in its discretion determine and (8) sell, transfer, pledge, make any agreement with respect to or otherwise deal with any of the Collateral as fully and completely as though Secured Party were the absolute owner thereof for all purposes; and

(iv) to do, at Secured Party’s option and Grantor’s expense, at any time, or from time to time, all acts and things which Secured Party may reasonably deem necessary to protect, preserve or realize upon the Collateral and Secured Party’s security interest therein in order to effect the intent of this Security Agreement, all as fully and effectively as Grantor might do.

 

10.


(b) Secured Party agrees that, except upon the occurrence and during the continuation of an Event of Default, it shall not exercise the power of attorney or any rights granted to Secured Party pursuant to this Section 6. Grantor hereby ratifies, to the extent permitted by law, all that said attorney shall lawfully do or cause to be done by virtue hereof. The power of attorney granted pursuant to this Section 6 is a power coupled with an interest and shall be irrevocable until the Secured Obligations are completely and indefeasibly paid and performed in full and Secured Party no longer has any commitment to make any Loans to Grantor.

(c) If Grantor fails to perform or comply with any of its agreements contained herein and Secured Party, as provided for by the terms of this Security Agreement, shall perform or comply, or otherwise cause performance or compliance, with such agreement, the reasonable expenses, including reasonable attorneys’ fees and costs, of Secured Party together with interest thereon at a rate of interest equal to the highest per annum rate of interest charged on the Loans, incurred in connection with such performance or compliance, shall be payable by Grantor to Secured Party within five (5) business days of demand and shall constitute Secured Obligations secured hereby.

7. RIGHTS AND REMEDIES UPON DEFAULT. Beginning on the date which is ten (10) business days after any Event of Default shall have occurred and while such Event of Default is continuing:

(a) Secured Party may exercise in addition to all other rights and remedies granted to it under this Security Agreement, the Notes, or the Purchase Agreement, all rights and remedies of a secured party under the UCC. Without limiting the generality of the foregoing, Grantor expressly agrees that in any such event Secured Party, without demand of performance or other demand, advertisement or notice of any kind (except the notice specified below of time and place of public or private sale) to or upon Grantor or any other person, may (i) reclaim, take possession, recover, store, maintain, finish, repair, prepare for sale or lease, shop, advertise for sale or lease and sell or lease (in the manner provided herein) the Collateral, and in connection with the liquidation of the Collateral and collection of the accounts receivable pledged as Collateral, use any Trademark, Copyright, or process used or owned by Grantor and (ii) forthwith collect, receive, appropriate and realize upon the Collateral, or any part thereof, and may forthwith sell, lease, assign, give an option or options to purchase or sell or otherwise dispose of and deliver said Collateral (or contract to do so), or any part thereof, in one or more parcels at public or private sale or sales, at any exchange or broker’s board or at any of Secured Party’s offices or elsewhere at such prices as it may deem commercially reasonable, for cash or on credit or for future delivery without assumption of any credit risk. Grantor further agrees, at Secured Party’s request, to assemble the Collateral and make it available to the Secured Party at places which Secured Party shall reasonably select, whether at Grantor’s premises or elsewhere. Secured Party shall apply the net proceeds of any such collection, recovery, receipt, appropriation, realization or sale as provided in Section 7(e), below, with Grantor remaining liable for any deficiency remaining unpaid after such application. Grantor agrees that Secured Party need not give more than twenty (20) days’ notice of the time and place of any public sale or of the time after which a private sale may take place and that such notice is reasonable notification of such matters.

 

11.


(b) As to any Collateral constituting certificated securities or uncertificated securities, if, at any time when Secured Party shall determine to exercise its right to sell the whole or any part of such Collateral hereunder, such Collateral or the part thereof to be sold shall not, for any reason whatsoever, be effectively registered under Securities Act of 1933, as amended (as so amended the “Act”), Secured Party may, in its discretion (subject only to applicable requirements of law), sell such Collateral or part thereof by private sale in such manner and under such circumstances as Secured Party may deem necessary or advisable, but subject to the other requirements of this Section 7(b), and shall not be required to effect such registration or cause the same to be effected. Without limiting the generality of the foregoing, in any such event Secured Party may, in its sole discretion, (i) in accordance with applicable securities laws, proceed to make such private sale notwithstanding that a registration statement for the purpose of registering such Collateral or part thereof could be or shall have been filed under the Act; (ii) approach and negotiate with a single possible purchaser to effect such sale; and (iii) restrict such sale to a purchaser who will represent and agree that such purchaser is purchasing for its own account, for investment, and not with a view to the distribution or sale of such Collateral or part thereof. In addition to a private sale as provided above in this Section 7(b), if any of such Collateral shall not be freely distributable to the public without registration under the Act at the time of any proposed sale hereunder, then Secured Party shall not be required to effect such registration or cause the same to be effected but may, in its sole discretion (subject only to applicable requirements of law), require that any sale hereunder (including a sale at auction) be conducted subject to such restrictions as Secured Party may, in its sole discretion, deem necessary or appropriate in order that such sale (notwithstanding any failure so to register) may be effected in compliance with the Bankruptcy Code and other laws affecting the enforcement of creditors’ rights and the Act and all applicable state securities laws.

(c) Grantor also agrees to pay all fees, costs and expenses of Secured Party, including, without limitation, attorneys’ fees, incurred in connection with the enforcement of any of its rights and remedies hereunder.

(d) Grantor hereby waives presentment, demand, protest or any notice (to the maximum extent permitted by applicable law) of any kind in connection with this Security Agreement or any Collateral.

(e) The Proceeds of any sale, disposition or other realization upon all or any part of the Collateral shall be distributed by Secured Party in the following order of priorities:

FIRST, to Secured Party in an amount sufficient to pay in full the costs of Secured Party in connection with such sale, disposition or other realization, including all fees, costs, expenses, liabilities and advances incurred or made by Secured Party in connection therewith, including, without limitation, attorneys’ fees;

SECOND, to Secured Party in an amount equal to the then unpaid Secured Obligations; and

FINALLY, upon payment in full of the Secured Obligations, to Grantor or its representatives, in accordance with the UCC or as a court of competent jurisdiction may direct.

 

12.


8. INDEMNITY. Grantor agrees to defend, indemnify and hold harmless Secured Party and its officers, employees, and agents against (a) all obligations, demands, claims, and liabilities claimed or asserted by any other party in connection with the transactions contemplated by this Security Agreement and (b) all losses or expenses in any way suffered, incurred, or paid by Secured Party as a result of or in any way arising out of, following or consequential to transactions between Secured Party and Grantor, whether under this Security Agreement or otherwise (including without limitation, reasonable attorneys fees and expenses), except for losses arising from or out of Secured Party’s gross negligence or willful misconduct.

9. REINSTATEMENT. This Security Agreement shall remain in full force and effect and continue to be effective should any petition be filed by or against Grantor for liquidation or reorganization, should Grantor become insolvent or make an assignment for the benefit of creditors or should a receiver or trustee be appointed for all or any significant part of Grantor’s property and assets, and shall continue to be effective or be reinstated, as the case may be, if at any time payment and performance of the Secured Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be restored or returned by any obligee of the Secured Obligations, whether as a “voidable preference,” “fraudulent conveyance,” or otherwise, all as though such payment or performance had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Secured Obligations shall be reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.

10. MISCELLANEOUS.

10.1 Waivers; Amendments. Any amendment of the Notes, the Purchase Agreement or this Security Agreement shall require the written consent of the Grantor and the Secured Party.

10.2 Termination of this Security Agreement. Subject to Section 9 hereof, this Security Agreement shall terminate upon the payment and performance in full of the Secured Obligations.

10.3 Successor and Assigns. This Security Agreement and all obligations of Grantor hereunder shall be binding upon the successors and assigns of Grantor, and shall, together with the rights and remedies of Secured Party hereunder, inure to the benefit of Secured Party, any future holder of any of the Secured Obligations and their respective successors and assigns. No sales of participations, other sales, assignments, transfers or other dispositions of any agreement governing or instrument evidencing the Secured Obligations or any portion thereof or interest therein shall in any manner affect the lien granted to Secured Party hereunder.

10.4 Governing Law. In all respects, including all matters of construction, validity and performance, this Security Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California applicable to contracts made and performed in such state, without regard to the principles thereof regarding conflict of laws, except to the extent that the UCC provides for the application of the law of a different jurisdiction.

 

13.


IN WITNESS WHEREOF, each of the parties hereto has caused this Security Agreement to be executed and delivered by its duly authorized officer on the date first set forth above.

 

ADDRESS OF GRANTOR

    BIOCEPT, INC., as Grantor
      By:   /s/ Stephen M. Coutts
      Printed Name:   Stephen M. Coutts
      Title:   President & CEO
TAXPAYER IDENTIFICATION NUMBER OF GRANTOR     JURISDICTION OF ORGANIZATION OF GRANTOR
      California

 

ACCEPTED AND ACKNOWLEDGED BY:

 

THE REISS FAMILY GST EXEMPT MARITAL DEDUCTION TRUST, as Secured Party

By:

  /s/ Claire Reiss

Printed Name:

  Claire Reiss

Title:

  Trustee

 

[SIGNATURE PAGE TO SECURITY AGREEMENT]


SCHEDULE A

LIENS EXISTING ON THE DATE OF THIS SECURITY AGREEMENT

None


SCHEDULE B

LOCATION OF GOODS

 

ENTITY

  

ADDRESS

Biocept, Inc.

   5810 Nancy Ridge Dr., San Diego, CA 92121


SCHEDULE C

LIST OF CHATTEL PAPER, INSTRUMENTS, AND

INVESTMENT PROPERTY

(CERTIFICATED SECURITIES)

None


SCHEDULE D

DEPOSIT ACCOUNTS, SECURITIES ACCOUNTS AND

COMMODITY ACCOUNTS

(Including Type of Account, Account Name, Account Number and Name and Address of Institution/Intermediary)

 

Description   Type of Account   Account Name   Account Number

California Coast Credit Union

  Savings   Biocept Inc.   7100001171

Address:

  California Coast Credit Union, PO Box 502080, San Diego, CA 92150-2080

SVB General Account

  Analysis Checking   Biocept Inc.   3300575742

Address:

  Silicon Valley Bank, 3003 Tasman Drive, Santa Clara, CA 95054

Merrill Lynch Checking

  WCMA   Biocept Inc.   778-07010

Address:

  Merrill Lynch, 150 Fayetteville Street, Suite 2000, Raleigh, NC ###-###-####

Merrill Lynch Investment

  WCMA/MLPA   Biocept Inc.   778-07007

Address:

  Merrill Lynch, 150 Fayetteville Street, Suite 2000, Raleigh, NC ###-###-####

Ulster Bank Account

  Corporate Checking   Biocept Europe   35180007

Address:

  Ulster Bank, Donegal County Business Centre, 2nd Floor, 12-14 Main Street
  Letterkenny, Co Donegal, Ireland  


SCHEDULE E

INTELLECTUAL PROPERTY

Issued/Granted Patents:

 

Attorney
Docket #

  

Outside
Counsel

  

Title

  

Inventor(s)

   Product    Country   Assign. Date/
Reel/Frame
   Date Filed/
Serial #
   Pub. Date/
Pub. #
   Date Issued/
Patent #

62685

   Fitch, Even, Tabin & Flannery    Method of Using an Improved Peptide Nucleic Acid Universal Library to Optimize DNA Sequence Hybridization   

S. Hahn

A. Patron

R. Fagnani

   PNA    Europe
(PCT)
  N/A    01/07/1999

99933646.4

   5/2/2001

EP1095054

   10/25/2006

EP 1,095,054 B1

               Korea

(PCT)

  N/A    01/07/1999

7000159

      3/7/2007

694914

62829

   Fitch, Even, Tabin & Flannery    Method of Making Biochips and the Biochips Resulting Therefrom    S. Hahn    Hydroarray    US   7/19/1999

010110/0277

   04/26/1999

09/299,831

   N/A    01/16/2001

6,174,683

66152

   Fitch, Even, Tabin & Flannery    Peptide Nucleic Acid Precursors and Methods of Preparing Same (CIP-abandoned)   

A. Patron

A. Pervin

   PNA    US   1/5/2000

010523/0685

   01/05/2000

09/479,320

   N/A    08/13/2002

6,433,134

66233

   Fitch, Even, Tabin & Flannery    Method of Making Biochips and The Biochips Resulting Therefrom   

R. Fagnani

S. Hahn

P. Tsinberg

   Hydroarray    Europe
(PCT)
  N/A    04/26/2000

00928450.6

   1/23/2002

EP1173620

   11/8/2006

EP 1,173,620 B1

               Germany   N/A    11/8/2006

600 31 772.2-08

   N/A    9/6/2007

DE 600 31 772 T2

               Korea
(PCT)
  N/A    04/26/2001

7013634/2001

      4/13/2007

709795

69905

   Fitch, Even, Tabin & Flannery    Three Dimensional Format Biochips   

R. Fagnani

S. Hahn

X. Dong

T. Pircher

S. Matsumoto

P. Tsinberg

   Hydroarray    Australia
(PCT)
  N/A    10/26/2001

2002246918

   N/A    1/11/2007

AU ###-###-####
B2

               Europe
(PCT)
  N/A    10/26/2001

01994529.4

   7/23/2003

EP1328810

   Published

No further
submissions

 

1


Attorney
Docket #

  

Outside
Counsel

  

Title

  

Inventor(s)

   Product    Country   Assign. Date/
Reel/Frame
   Date Filed/
Serial #
   Pub. Date/
Pub. #
   Date Issued/
Patent #

71716

   Fitch, Even, Tabin & Flannery    Microwell Biochip   

P. Tsinberg

P. Roycroft

Y. Gerassi

S. Hahn

   Microwell    Europe
(PCT)
  N/A    10/15/2002

2772545.0-2204

   8/11/2004

EP 1,444,500

   6/11/08

1,444,500

               Japan
(PCT)
  N/A    10/15/2002

2003-536,713

   3/3/2005

2005-506,530

   Published

No further
submissions

72711

   Fitch, Even, Tabin & Flannery    Methods and Gel Compositions for Encapsulating Living Cells and Organic Molecules   

S. Hahn

R. Fagnani

X. Dong

C. Edman

P. Tsinberg

   Hydrogel    US   8/7/2003

013857/0723

   04/02/2003

10/398,725

   2/12/2004

2004/0029241

   02/6/2007

7,172,866

               Europe

(PCT)

  N/A    04/02/2002

02763911.1-2405

   1/2/2004

EP1373472

   6/27/2007

1,373,472 – Filed
in GE, FR, GB

               Germany   N/A    6/27/2007

602 20 893.9-08

   N/A    3/6/2008

DE60220893T2

81633

   Fitch, Even, Tabin & Flannery    Microarray Hybridization Device Having Bubble-Fracturing Elements   

S. Hahn

J. Steadman

P. Tsinberg

T. Watanaskul

Y. Gerassi

   Hybridization
Device
   US   11/24/2003

014756/0001

   11/24/2003

10/722,290

   05/26/2005

2005/0112589

   07/3/2007

7,238,521

               Europe
(PCT)
  N/A    11/03/2004

04800599.5

   8/9/2006

EP1687080

   6/24/08

1,687,080

81634

   Fitch, Even, Tabin & Flannery    Reflective Substrate and Algorithms for 3D Biochip    D. Rachlin    Substrate    US   11/4/2004

015338/0315

   09/16/2003

10/664,248

   Filed w/Non-
Publication
Notice
   04/3/2007

7,198,901

81674

   Fitch, Even, Tabin & Flannery    Alleviation of Non-Specific Binding in Microarray Assays   

Y. Gerassi

P. Tsinberg

   Protein    US   11/3/2004

015332/0733

   8/19/2004

10/922,387

   2/23/2006

2006/0040407

   08/21/07

7,258,990

               Europe
(PCT)
  N/A    2/21/2007

05,808,506.9

   5/23/2007

1,787,120

   Abandoned

81721

   Fitch, Even, Tabin & Flannery   

Microwell Biochip

(Cont. 71716)

  

Y. Gerassi

S. Hahn

P. Roycroft

P. Tsinberg

   Microwell    US   10/14/2004

015248/0196

   04/12/2004

10/823,021

   9/30/2004

2004/0191891

   05/15/2007

7,217,520

81736

   Fitch, Even Tabin & Flannery    mRNA Expression Analysis    T. Pircher    Expression
Analysis
   Europe
(PCT)
  N/A    6/18/2004

04776771.0-2405

   4/26/06

EP1649060

   Abandoned

 

2


Pending Applications:

 

Attorney
Docket #

  

Outside
Counsel

  

Title

  

Inventor(s)

  

Product

   Country   Assign. Date/
Reel/Frame
   Date Filed/
Serial #
   Pub. Date/
Pub. #
   Date Issued/
Patent #

62685

   Fitch, Even, Tabin & Flannery    Method of Using an Improved Peptide Nucleic Acid Universal Library to Optimize DNA Sequence Hybridization   

S. Hahn

A. Patron

R. Fagnani

   PNA    WO
(PCT)
  N/A    01/07/1999

PCT/US99/14969

   01/20/2000

WO0002899

   N/A
               Japan

(PCT)

  N/A    01/07/1999

2000-559,128

   7/9/2002

2002-520,008

   Published

66233

   Fitch, Even, Tabin & Flannery    Method of Making Biochips and The Biochips Resulting Therefrom   

R. Fagnani

S. Hahn

P. Tsinberg

   Hydroarray    WO

(PCT)

  N/A    04/26/2000

PCT/US001/11282

   11/02/2000

WO/0065097

   N/A
               Japan

(PCT)

  N/A    4/26/2000

2000-614,431

   /2002

2002-543,398

   Published

69905

   Fitch, Even, Tabin & Flannery    Three Dimensional Format Biochips   

R. Fagnani

S. Hahn

X. Dong

T. Pircher

S. Matsumoto

P. Tsinberg

   Hydroarray    WO
(PCT)
  N/A    10/26/2001

PCT/US01/51265

   8/1/2002

WO02059372

   N/A
               China

(PCT)

  N/A    10/26/2001    01 994 529.4    Published
               Japan

(PCT)

  N/A    10/26/2001

2002-559,854

   6/17/2004

2004-518,138

  
               Korea

(PCT)

  N/A    10/26/2001

7008285/2002

   Pending   

71716

   Fitch, Even, Tabin & Flannery    Microwell Biochip   

P. Tsinberg

P. Roycroft

Y. Gerassi

S. Hahn

   Microwell    WO
(PCT)
  N/A    10/15/2001

PCT/US02/32751

   04/24/2003

WO2003034026

   N/A

71726

   Fitch, Even, Tabin & Flannery    Three-Dimensional Format Biochips (CIP)   

R. Fagnani

S. Hahn

X. Dong

T. Pircher

S. Matsumoto

P. Tsinberg

   Hydroarray    US   5/28/2002

012736/0060

   10/25/2001

10/054,728

   2/17/2005

2005/0037343

   Published

No Further
Submissions

 

3


Attorney
Docket #

  

Outside
Counsel

  

Title

  

Inventor(s)

  

Product

   Country   Assign. Date/
Reel/Frame
   Date Filed/
Serial #
   Pub. Date/
Pub. #
   Date Issued/
Patent #

72711

   Fitch, Even, Tabin & Flannery    Methods and Gel Compositions for Encapsulating Living Cells and Organic Molecules   

S. Hahn

R. Fagnani

X. Dong

C. Edman

P. Tsinberg

   Hydrogel    WO
(PCT)
  N/A    04/02/2002

PCT/US02/10411

   10/17/2002

WO2002/081662

   N/A
               Canada

(PCT)

  N/A    04/02/2002

2,443,060

   Published    Maintain –
no further
submissions
               Israel

(PCT)

  N/A    04/02/2002

158128

      N/A
               Japan

(PCT)

  N/A    04/02/2002

2002-580,026

   11/4/2004

2004-533,500

   N/A

81633

   Fitch, Even, Tabin & Flannery    Microarray Hybridization Device   

S. Hahn

J. Steadman

P. Tsinberg

T. Watanaskul

Y. Gerassi

   Hybridization Device    WO   N/A    11/03/2004

PCT/US04/036475

   6/16/2005

WO2005/053827

   N/A
               China
(PCT)
  N/A    5/22/2006

200480034517.7

   12/20/2006

CN1882382A

   Abandoned
               Hong
Kong
  N/A    6/5/2007

07105921.6

   9/28/2007

1100820

   Abandoned
               India
(PCT)
  N/A    09/21/2006

2316/CHENP/2006

      Abandoned
               Japan
(PCT)
  N/A    11/7/2006

2006-541216

   6/14/2007

2007-515627

   Abandoned
               Korea
(PCT)
  N/A    6/22/2006

7012472/2006

   Pending    Abandoned

 

4


Attorney
Docket #

  

Outside
Counsel

  

Title

  

Inventor(s)

  

Product

   Country   Assign. Date/
Reel/Frame
   Date Filed/
Serial #
   Pub. Date/
Pub. #
   Date Issued/
Patent #

81665

   Fitch, Even, Tabin & Flannery    Detection of Chromosomal Disorders   

S. Hahn

Z. Xie

T. Watanaskul

   Chromosomal Disorder Detection    US   10/4/2004

015217/0311

   05/05/2004

10/840,208

   11/10/2005

2005/0250111

   No Further
Submissions
               WO   N/A    04/18/2005

PCT/US2005/013070

   11/24/2005

WO2005/111237

   N/A
               China
(PCT)
  N/A    12/21/06

200580020530.1

   6/13/2007

CN1981052A

  
               Hong
Kong
  N/A    11/6/07

07112041.7

   3/14/08

1,106,553

  
               Europe
(PCT)
  N/A    12/4/2006

05740274.4

   3/7/2007

EP1759011

  
               India
(PCT)
  N/A    4473/CHENP/2006    Pending   
               Japan
(PCT)
  N/A    11/6/2006

2007-511389

   12/13/2007

2007-535928

  
               Korea
(PCT)
  N/A    12/1/2006

7025434/2006

   Pending   

81671

   Fitch, Even, Tabin & Flannery    Detection of STRP Such as Fragile X Syndrome    S. Hahn    Chromosomal Disorder Detection    US   4/21/2004

014538/0289

   03/01/2004

10/791,209

   9/1/2005

2005/0191636

   Abandoned
               WO   N/A    02/28/2005

PCT/US05/007049

   09/15/2005

WO2005/085476

   N/A
               China
(PCT)
  N/A    08/31/2006

200580006466.1

   03/23/2007

CN1926247A

  
               Hong
Kong
  N/A    6/26/2007

07106812.6

   11/2/2007

1,102,059

  
               Europe
(PCT)
  N/A    09/21/2006

05,724,566.4

   11/22/2006

EP1723261

  
               India
(PCT)
  N/A    2/28/2005

3600/CHENP/2006

   Pending   
               Japan
(PCT)
  N/A    01/16/2007

501418993

   9/13/2007

2007-525998

  
               Korea
(PCT)
  N/A    10/2/2006

7020635/2006

   Pending   

 

5


Attorney
Docket #

  

Outside
Counsel

  

Title

  

Inventor(s)

  

Product

   Country   Assign. Date/
Reel/Frame
   Date Filed/
Serial #
   Pub. Date/
Pub. #
   Date Issued/
Patent #

81672

   Fitch, Even, Tabin & Flannery    Protein Microarrays    P. Tsinberg    Protein    US   11/18/2004

015391/0794

   8/17/2004

10/921,073

   2/23/06

2003/0040377

   N/A
               WO   N/A    8/9/2005

PCT/US2005/028225

   3/2/2006

WO2006/023324

   N/A
               China
(PCT)
  N/A    2/12/2007

200580027771.9

   Pending    No further
submissions
               Hong
Kong
  N/A    3/26/2008

08103346.7

   Pending    No further
submissions
               Europe
(PCT)
  N/A    2/21/2007

05,784,703.0

   5/2/2007

1,779,114

   No further
submissions
               India
(PCT)
  N/A    8/9/2005

1108/CHENP/2007

   Pending    No further
submissions
               Japan
(PCT)
  N/A    4/19/2007

2007-527867

   4/3/08

2008-510165

   No further
submissions
               Korea
(PCT)
  N/A    3/15/2007

7006000/2007

      No further
submissions

81673

   Fitch, Even, Tabin & Flannery    Microarrays Utilizing Hydrogels    P. Tsinberg    Hydrogel    US   10/18/2004

0152561/0623

   8/19/2004

10/922,391

   2/23/06

2006/0040274

   No further
submissions
               WO   N/A    8/9/2005

PCT/US2005/028224

   3/2/06

WO2006/023323

   N/A
               China
(PCT)
  N/A    2/25/2007

200580028415.9

   9/26/07

CN101044401A

   No further
submissions
               Hong
Kong
  N/A    3/26/2008

08103349.4

   Pending    No further
submissions
               Europe
(PCT)
  N/A    2/21/2007

05,784,526.5

   5/2/2007

1,779,113

   No further
submissions
               India
(PCT)
  N/A    10/2007

1144/CHENP/2007

   Pending    No further
submissions
               Japan
(PCT)
  N/A    2/19/2007

2007-527866

   4/3/08

2008-510164

   No further
submissions
               Korea
(PCT)
  N/A    3/15/2007

7006001/2007

   Pending    No further
submissions

 

6


Attorney
Docket #

  

Outside
Counsel

  

Title

  

Inventor(s)

  

Product

   Country   Assign. Date/
Reel/Frame
   Date Filed/
Serial #
   Pub. Date/
Pub. #
   Date Issued/
Patent #

81674

   Fitch, Even, Tabin & Flannery    Alleviation of Non-Specific Binding in Microarray Assays   

Y. Gerassi

P. Tsinberg

   Protein    WO   N/A    8/11/2005

PCT/US2005/028690

   3/2/2006

WO2006/023383

   N/A
               China
(PCT)
  N/A    2/25/2007

200580028345.7

   8/29/2007

CN101027559A

   Abandoned
               Hong
Kong
  N/A    11/23/2007

07112786.6

   4/3/2008

1,107,400

   Abandoned
               India
(PCT)
  N/A    10/2007

1142/CHENP/2007

   Pending    Abandoned
               Japan
(PCT)
  N/A    2/19/2007

2007-527889

   4/3/08

2008-510167

   Abandoned
               Korea
(PCT)
  N/A    3/16/2007

7006187/2007

   Pending    Abandoned

81736

   Fitch, Even, Tabin & Flannery    mRNA Expression Analysis    T. Pircher    Expression Analysis    WO   N/A    06/21/2004

PCT/US04/019559

   01/06/2005

WO2005/001139

   N/A
               Japan
(PCT)
  N/A    12/27/2005

2006-517413

   11/29/2007

2007-534298

   Abandoned

81835

   Fitch, Even, Tabin & Flannery    3D Format Biochips and Method of Use (CIP 71726)    T. Pircher    Cell Separation    US   2/4/2005

015660/0316

   12/16/2004

11/015,459

   05/12/2005

2005/0100951

   N/A

86357

   Fitch, Even, Tabin & Flannery    Methods and Gel Compositions for Encapsulating Living Cells and Organic Molecules (DIV of 72711)   

S. Hahn

R. Fagnani

X. Dong

C. Edman

P. Tsinberg

   Hydrogel    US   N/A    02/01/2007

11/670,061

   6/21/2007

2007/0141164

   Response to
Office Action
Filed

BIOE-001/

00US

   Cooley, Godward, Kronish    Recovery of Rare Cells Using a Microchannel Apparatus with Patterned Posts (Foreign see 86213)   

Z. Tang

R. Bhatt

P. Tsinberg

   MEMs Channel    US   3/11/2005

015884/0336

   1/18/2005

11/038,920

   7/20/2006

2006/0160243

   Response to
Office Action
filed

 

7


Attorney
Docket #

  

Outside
Counsel

  

Title

  

Inventor(s)

  

Product

   Country   Assign. Date/
Reel/Frame
   Date Filed/
Serial #
   Pub. Date/
Pub. #
   Date Issued/
Patent #

BIOE-001/

01US

   Cooley, Godward, Kronish    Detection or Isolation of Target Molecules Using a Microchannel Apparatus (CONT. 81816)   

Z. Tang

R. Bhatt

P. Tsinberg

   MEMs Channel    US   N/A    7/19/2006

11/458,668

   11/9/2006

2006/0252087

   Response to
Office Action
filed

BIOE-001/

01WO

               WO   N/A    7/18/2007

PCT/US07/073817

   01/24/2008

WO2008/011486

   N/A

BIOE-001/

03US

   Cooley, Godward, Kronish    Cell Separation Using Microchannel Having Patterned Posts (Incorps. 81816 & BIOE-001/02US)   

P. Tsinberg

Z. Tang

R. Bhatt

   MEMs Channel    US
(PCT)
  Pending    7/18/2007

11/814,276

   Pending    Pending Exam
Requested

BIOE-001/

03WO

               WO   N/A    1/5/2006

PCT/US2006/000383

   07/27/2006

WO2006/078470

   N/A

BIOE-001/

03CN

               China
(PCT)
  N/A    1/5/2006

200680002401.4

   1/9/2008

CN101102847A

  

BIOE-001/

003EP

               Europe
(PCT)
  N/A    5/31/2007

06717562.0

   Pending   

BIOE-001/

03IN

               India
(PCT)
  N/A    8/14/2007

2991/KOLNP/2007

   Pending   

BIOE-001/

03IL

               Israel
(PCT)
  N/A    Preparing to File      

BIOE-001/

03JP

               Japan
(PCT)
  N/A    Preparing to File      

BIOE-001/

03KR

               Korea
(PCT)
  N/A    Preparing to File      

BIOE-001/

03TW

               Taiwan   N/A    5/2/2006

95115566

   11/16/2007

200742612

   Request for Exam.
Due 5/2/09

 

8


Attorney
Docket #

  

Outside
Counsel

  

Title

  

Inventor(s)

  

Product

   Country   Assign. Date/
Reel/Frame
   Date Filed/
Serial #
   Pub. Date/
Pub. #
   Date Issued/
Patent #

BIOE-002/

00WO

   Cooley, Godward, Kronish    Isolation of Cells or the Like from Bodily Fluids (Beads)   

R. Bhatt

P. Tsinberg

   Cell Separation    WO   N/A    12/21/2005

PCT/US2005/046961

   7/6/2006

WO2006/071824

   N/A – No
National
Filing

BIOE-002/

00US

   Cooley, Godward, Kronish    Isolation of Cells or the Like from Bodily Fluids (Beads)   

R. Bhatt

P. Tsinberg

   Cell Separation    US   3/4/2005

015838/0143

   12/23/2004

11/021,304

   6/29/2006

2006/0141045

   Issue Fee
Paid

Awaiting
Published

BIOE-003/

00US

   Cooley, Godward, Kronish    Trophoblast Preservation/ Pretreatment Medium and Method    T. Pircher    Transport Medium    US   4/24/2006

017518/0416

   3/22/2006

11/277,218

   9/27/2007

2007/0224588

   Abandoned

BIOE-004/

00US

   Cooley, Godward, Kronish    Isolating Fetal Trophoblasts (Mucus Dissolution)   

T. Pircher

R. Fagnani

   Cell Separation    US   5/1/2006

017556/0667

   3/23/2006

11/277,288

   9/27/2007

2007/0224597

   Abandoned

BIOE-004/

01WO

               WO   N/A    3/22/2007

PCT/US2007/64705

   10/4/2007

WO2007/112281

   N/A

BIOE-005/

00US

   Cooley, Godward, Kronish    Device for Cell Separation and Analysis and Method of Using (covered)   

P. Tsinberg

Z. Tang

   MEMs Channel    US   2/6/2006

017238/0401

   01/12/2006

11/331,988

   7/12/2007

2007/0161051

   Pending
Published

BIOE-005/

01WO

               WO   N/A    1/12/2007

PCT/US2007/060518

   1/19/2007

WO2007/082302

   N/A

BIOE-005/

01CN

               China
(PCT)
     Preparing to File      

BIOE-005/

01EP

               Europe
(PCT)
     Preparing to File      

BIOE-005/

01JP

               Japan
(PCT)
     Preparing to File      

BIOE-005/

01IN

               India
(PCT)
     Preparing to File      

BIOE-005/

01KR

               Korea
(PCT)
     Preparing to File      

BIOE-006/

00US

   Cooley, Godward, Kronish    Enrichment of Circulating Fetal DNA (BAYLOR)    F. Bischoff    Cell Separation    US   8/23/2007

019739/0966

   4/11/2007

11/734,224

   10/18/2007

2007/0243549

   Abandoned

BIOE-006/

01WO

               WO   N/A    4/11/2007

PCT/US2007/66475

   10/25/2007

WO2007/121276

   N/A

 

9


Attorney
Docket #

  

Outside
Counsel

  

Title

  

Inventor(s)

  

Product

   Country   Assign. Date/
Reel/Frame
   Date Filed/
Serial #
   Pub. Date/
Pub. #
   Date Issued/
Patent #

BIOE-006/

01CN

               China
(PCT)
          

BIOE-006/

01EP

               Europe
(PCT)
          

BIOE-006/

01JP

               Japan
(PCT)
          

BIOE-006/

01IN

               India
(PCT)
          

BIOE-006/

01KR

               Korea
(PCT)
          

BIOE-007/

00US

   Cooley, Godward, Kronish    Identification and Isolation of Fetal Cells and Nucleic Acid (PROVISIONAL)    F. Bischoff    Cell Separation    US      9/21/2007

60/974,392

   N/A    Application Filed

BIOE-009/

00US

   Cooley, Godward, Kronish    Non-Invasive Prenatal Genetic Screen   

R. Bhatt

W. Fan

R. Tim

F. Bischoff

   Cell Separation    US   020377/0504    12/7/2007

11/952,459

   Converted
to PCT
and US
   Application Filed

National Phase
Due 6/7/2009

BIOE-009/

01WO

               WO      12/7/2007

PCT/US2007/86862

      N/A

BIOE-010/

01US

   Cooley, Godward, Kronish    Non-Invasive Detection of Endometrial Cancer (Priority date of 5/2/07)   

H. Radisch

Q. Le

   Cell Separation    US   Pending    05/02/2008

12/114,584

      Application Filed

Abandoned

               WO      5/1/2008

PCT/US2008/062286

      N/A

BIOE-013/

00US

   Cooley Godward Kronish   

In-Situ Hybridization to Detect RNA and DNA Markers

(PROVISIONAL)

  

R. Bhatt

W. Fan

R. Tim

   Cell Separation    US   01/04/2008

020319/0009

   8/3/2007

60/953,812

   N/A    National Phase
Due 2/3/2010

BIOE-014/

00US

   Cooley Godward Kronish    Non-Invasive Isolation of Fetal Nucleic Acid (Partial Lysis) (PROVISIONAL)   

R. Bhatt

K. Kosco

I. Postor

W. Fan

   Cell Separation    US      11/1/2007

60/984,698

   N/A    Application Filed

 

10


Attorney
Docket #

  

Outside
Counsel

  

Title

  

Inventor(s)

  

Product

   Country    Assign. Date/
Reel/Frame
   Date Filed/
Serial #
   Pub. Date/
Pub. #
   Date Issued/
Patent #

BIOE-0015/

00US

   Cooley Godward Kronish   

Method for Isolating Cell Free Apoptotic or Fetal Nucleic Acids

(PROVISIONAL)

  

R. Bhatt

W. Fan

   Cell Separation    US    6/9/2008

021068/0429

   2/12/2008

61/028,064

   N/A    Application Filed

BIOE-0016/

00US

   Cooley Godward Kronish   

Device Utilizing Electric Field and Size Cut-Off for the Separation of Changed Species (Electrophoresis)

(PROVISIONAL)

   Z. Tang    Cell Separation    US    5/19/2008

020968/0447

   4/7/2008

61/043,028

   N/A    Application Filed

Abandoned

BIOE-018/

00US

   Cooley Godward Kronish    Two-Stage Enrichment of Cell Free Fetal DNA in Maternal Plasma (PROVISIONAL)    F. Bischoff    Cell Separation    US       1/30/2008

61/024,872

   N/A    Application Filed

 

11


Pending Drafts:

 

Attorney

Docket #

  

Outside

Counsel

  

Title

  

Inventor(s)

   Product    Country    Status

BIOE-012/

00US

   Cooley Godward Kronish    Collection, Separation, Purification and Testing of Trophoblasts    T. Pircher    Cell Separation    US    Abandoned

BIOE-011/

00US

   Cooley Godward Kronish    Method and Kit for Cell Separation (Double-Sided Slide)    R. Bhatt    Cell Separation    US    Abandon

 

12


TRADEMARKS

Registered:

 

Outside Counsel

   Mark    Int’l Class(es)    Registry    Date Filed/
Serial #
   Date Registered/
Registration #

US

Cooley Godward Kronish LLP

   Biocept®    9    Principal    03/22/2002

78/116,876

   08/31/2004

2,880,222

Cooley Godward Kronish LLP

   Biocept Laboratories®    9/42    Principal    05/04/2004

78/412,723

   10/17/2006

3,159,956

Cooley Godward Kronish LLP

   CEE®    44    Principal    06/10/2005

78/648,645

   10/30/2007

3,326,287

Cooley Godward Kronish LLP

   ChipCalc®    9    Principal    12/15/2003

78/341,146

   09/20/2005

2,999,101

Cooley Godward Kronish LLP

   HydroArray®    1/9    Principal    08/01/2003

78/282,032

   03/22/2005

2,934,749

Cooley Godward Kronish LLP

   3D HydroArray®    1/9    Principal    09/12/2003

78/299,957

   09/27/2005

3,000,775

Cooley Godward Kronish LLP

   Engineering new directions
in diagnostics™
   42/44    Principal    5/27/2008    07/01/08

3,458,860

European Community (CTM)

Cooley Godward Kronish LLP

   preCEEd®    9/42    N/A    11/16/2005

4724101

   11/16/2006

4724101

Japan

Cooley Godward Kronish LLP

   preCEEd®    9/44    N/A    11/11/2005

2005-106514

   05/11/2007

5046520

 

13


Pending Registration:

 

Outside Counsel

   Mark    Int’l
Class
   Date Filed/
Serial #
  

Status

US

Cooley Godward Kronish LLP

   FirstCEE™    1/9/44    3/19/2007

77/134,792 (IC 001)

77/134793 (IC 009)

77/134,796 (IC 044)

  

Allowed for all classes;

SOU for Class 1&9 due 10/30/08;

SOU for Class 44 due 1/1/09 (2nd ext.)

Cooley Godward Kronish LLP

   I.D. ™    1/5/44    05/15/2008

77/475,119

   Awaiting Office Communication

Cooley Godward Kronish LLP

   preCEEd™    1/9/44    06/10/2005

78/648,632 (IC 001/9)

   Allowed 7/24/07; Statement of Use due 1/24/09 (3rd ext.)
         07/17/200678/931,082
(IC 044)
   Allowed 5/22/07; Statement of Use due 11/22/08 (3rd ext.)

European Community (CTM)

Cooley Godward Kronish LLP

   CEE™    9/42    11/17/2005

4725545

   To be re-filed with more stylized format

Cooley Godward Kronish LLP

   FIRSTCEE™    1/5/9/44    09/17/2007

6282719

   Replied to O.A. 11/25/07

Japan

Cooley Godward Kronish LLP

   CEE™    9/42    11/11/2005

2005-106515

   Replied to O.A. 12/23/06

Cooley Godward Kronish LLP

   FIRSTCEE™    1/9/44    09/18/2007

2007-098571

   Replied to Office Action 5/16/08 (all classes)

 

14